General Information of Drug (ID: DMXC30P)

Drug Name
MS417 Drug Info
Synonyms
MS417; Methyl [(6s)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6h-Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-6-Yl]acetate; 916489-36-6; GGRCIHACOIMRKY-HNNXBMFYSA-N; 0S6; 4f3i; US9125915, compound 6; GTPL7512; CHEMBL3769755; SCHEMBL12228301; CHEBI:83406; BDBM179283; MS-417; ZINC95921068; HY-111139; CS-0034388; Methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
59190723
ChEBI ID
CHEBI:83406
TTD Drug ID
DMXC30P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CPI-0610 DMPXOYJ Myelofibrosis 2A20.2 Phase 3 [2]
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [2]
PLX2853 DMX168L Acute myeloid leukaemia 2A60 Phase 1/2 [3]
RVX-208 DM1LO8K Alzheimer disease 8A20 Phase 1/2 [2]
INCB57643 DMBGU7V Advanced malignancy 2A00-2F9Z Phase 1/2 [3]
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [3]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [4]
GSK525762 DMPAWBN Haematological malignancy 2B33.Y Phase 1 [2]
TEN010 DM4UOY5 Advanced solid tumour 2A00-2F9Z Phase 1 [2]
AZD5153 DMW4GM2 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bromodomain-containing protein 4 (BRD4) TTRA6BO BRD4_HUMAN Inhibitor [1]

References

1 Down-regulation of NF- B transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51.
2 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.